phrykt

Eupraxia Pharmaceuticals Inc. (EPRX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of EPRX were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Eupraxia Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EPRX

68 funds and institutions reported EPRX shares worth $164M at the end of Q2 2026, about 70% of the company. The largest holder is Beutel, Goodman & Co Ltd. with 10.2%.

Funds and institutions (13F) 70%Everyone else 30%

10 largest owners, by share of the company

Beutel, Goodman & Co Ltd.10.2%
Affinity Asset Advisors, LLC4.6%
Balyasny Asset Management L.P.3.8%
Vivo Capital, LLC3.8%
Scotia Capital Inc.3.8%
PFM Health Sciences, LP3.4%
Great Point Partners LLC3.4%
Jupiter Topco LLC2.9%
Rubric Capital Management LP2.4%
Ikarian Capital, LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Beutel, Goodman & Co Ltd.3.63M10.18%$23.8M-1%
Affinity Asset Advisors, LLC1.65M4.63%$10.9M+4%
Balyasny Asset Management L.P.1.35M3.79%$8.9MNo change
Vivo Capital, LLC1.35M3.79%$8.9MNo change
Scotia Capital Inc.1.34M3.77%$8.8M+0%
PFM Health Sciences, LP1.21M3.40%$8M+124%
Great Point Partners LLC1.20M3.37%$7.9MNo change
Jupiter Topco LLC1.05M2.93%$6.9MNew
Rubric Capital Management LP867,4242.43%$5.7M+26%
Ikarian Capital, LLC809,7412.27%$5.4M-33%
Woodline Partners LP746,8642.10%$4.9M+70%
Point72 Asset Management, L.P.730,2842.05%$4.8M-25%
Ameriprise Financial Inc711,0241.99%$4.7M+36%
Redmile Group, LLC611,4001.72%$4M-13%
Seven Fleet Capital Management LP610,7851.71%$4M+41%
UBS Group AG519,2111.46%$3.4M-32%
Citadel Advisors LLC502,0111.41%$3.3M+118%
Millennium Management LLC441,5861.24%$2.9MNew
Alyeska Investment Group, L.P.375,0001.05%$2.5MNo change
Picton Mahoney Asset Management360,8781.01%$2.4MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No EPRX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EPRX short interest

6.25M EPRX shares are sold short. Over the last 12 reports the number of shares short went up 75%.

As of Oct 30, 2026, 6.25M EPRX shares were sold short, down 4.5% from the report before. At the average daily volume of 602,929 shares, buying them all back would take about 10.4 trading days (days to cover).

Shares short

6.25MMay 15Oct 308.19M

Days to cover

10.4May 15Oct 3032.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.25M–-4%602,92910.4
Oct 15, 20266.54M–-4%1.25M5.2
Sep 30, 20266.80M–-10%614,40811.1
Sep 15, 20267.58M–+7%673,95511.2
Aug 31, 20267.11M–+12%385,47118.4
Aug 14, 20266.34M–+5%220,31028.8
Jul 31, 20266.04M–+2%465,25913.0
Jul 15, 20265.92M–+8%230,01825.7
Jun 30, 20265.46M–+19%607,3489.0
Jun 15, 20264.60M–+13%282,50316.3
May 29, 20264.08M–+15%332,60012.3
May 15, 20263.56M–+16%149,95023.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Eupraxia Pharmaceuticals financials

Famous investors that hold EPRX

2 of the 50 well-known investors we track reported holding EPRX in their latest 13F filing. The largest position is Ken Griffin's, worth $8.9M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026978,875$8.9M0.0%+95%
Israel Englander · Millennium ManagementQ3 2026105,436$961K0.0%-76%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Eupraxia Pharmaceuticals Inc. (EPRX) stock

Who owns the most EPRX stock?

The largest reported owner of Eupraxia Pharmaceuticals Inc. (EPRX) is Beutel, Goodman & Co Ltd., with 10.2% of the company. In total, 68 funds and institutions reported holding EPRX at the end of Q2 2026, together about 70% of the shares. See the largest owners.

Are EPRX insiders buying or selling?

No EPRX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in EPRX?

As of Oct 30, 2026, 6.25M EPRX shares were sold short, down 4.5% from the report before. At the average daily volume of 602,929 shares, buying them all back would take about 10.4 trading days (days to cover). See the history.

Which famous investors hold EPRX?

2 of the 50 well-known investors we track reported EPRX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $8.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.